רווח תפעולי EBITDA: krystalbio.com (KRYS)

Krystal Biotech, Inc. (KRYS) targets patients with severe genetic skin pathologies, receiving payments from insurance funds. The company's financial stability is tied to the commercialization of the drug Vyjuvek, which creates a risk of single-product dependency. The EBITDA volume demonstrates the cash flow from core operations, where the 235.51 metric determines this level, confirming its status as a leader in gene therapy.

This indicator is calculated by adjusting operating profit for non-cash depreciation and amortization, allowing investors to assess the actual scale of generated cash flow and filter out overvalued assets. For Krystal Biotech, Inc. (KRYS), which is implementing breakthrough gene therapy in dermatology, the consolidated EBITDA serves as a marker for the effectiveness of innovation commercialization, where rapid growth in this line may signal a risk of overpaying for the stock.